


## Abstract

Phenylalanine enamide derivatives of formula (1) are described:



5

wherein  $R^1$  is a  $-\text{CH}_3$ ,  $-(\text{CH}_2)_3\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CH}_2\text{OCH}_3$ ,  
 $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$ ,

$-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \diagdown \\ \text{---} \text{O} \text{---} \end{array} \text{---}$  or  $-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \diagdown \\ \text{---} \text{N}(\text{CH}_3) \text{---} \end{array} \text{---}$

10 group;

and the salts, solvates and N-oxides thereof.

Compounds according to the invention are potent and selective inhibitors  
of  $\alpha_4$  integrins. The compounds are of use in modulating cell adhesion  
and in particular are of use in the prophylaxis and treatment of diseases or  
disorders including inflammation in which the extravasation of leukocytes  
plays a role and the invention extends to such a use and to the use of the  
compounds for the manufacture of a medicament for treating such  
diseases or disorders.

20